BYSIのチャート
BYSIの企業情報
| symbol | BYSI |
|---|---|
| 会社名 | BeyondSpring Inc （ビヨンドスプリング） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product Plinabulin into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe grade 4 neutropenia and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent which induces T-cell activation. The Company's IkappaB kinase (IKK) program BPI-003 is based on a small molecule inhibitor of IKK a protein kinase. ビヨンドスプリングは米国のバイオ医薬品メ―カ―。末期の免疫性腫瘍の治療薬も含む、革新的ながん治療薬の開発に注力する。主要製品候補の「プリナブリン」は、進行性非小細胞肺がんの治療薬及び好中球減少症の予防薬として臨床段階中である。また、モノクロ―ナル抗体医薬品のニボルマブとプリナブリンを組み合わせた治療薬も開発中。本社はニューヨーク。 BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City. |
| 本社所在地 | 28 Liberty Street 39th Floor New York NY 10005 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 646-528-4184 |
| 設立年月日 | 41944 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 38人 |
| url | www.beyondspringpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bysi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -64.95400 |
| 終値（lastsale） | 23.5345 |
| 時価総額（marketcap） | 528013028.719 |
| 時価総額 | 時価総額（百万ドル） 529.95460 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 508.41660 |
| 当期純利益 | 当期純利益（百万ドル） -58.02300 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 March 2018 Beyondspring Inc revenues was not reported. Net loss decreased 71% to $13.7M. Lower net loss reflects Research_Development decrease of 70% to $14.1M (expense) General and administrative decrease of 30% to $728K (expense) Foreign Exchange Gain Net increase from $74K to $332K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.01 to -$0.77. |
BYSIのテクニカル分析
BYSIのニュース
During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect 2022/04/23 18:00:00 Marketing Sentinel
During the last session, BeyondSpring Inc. (NASDAQ:BYSI)’s traded shares were 0.32 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $1.95, reflecting an intraday gain of 3.72% or $0.07. The 52-week high for the BYSI share is $33.00, that puts it down -1592.31 … During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect Read More »
Li Auto, Luckin Coffee and BeyondSpring headline a SEC watch list for accounting compliance 2022/04/21 19:33:16 Seeking Alpha
The SEC added 17 more firms to the Holding Foreign Companies Accountable Act list of companies. Read more about the watch list.
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript 2022/04/14 17:06:06 Seeking Alpha
BeyondSpring Inc. (NASDAQ:NASDAQ:BYSI) Q4 2022 Earnings Conference Call April 14, 2022, 08:00 AM ET Company Participants Ashley Sierchio - LifeSci Advisors Lan Huang - Co-Founder, Chairman…
BeyondSpring Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:BYSI) 2022/04/14 16:56:48 Seeking Alpha
The following slide deck was published by BeyondSpring Inc.
Beyondspring, Inc. (BYSI) Q4 2021 Earnings Call Transcript 2022/04/14 13:50:03 AlphaStreet
Beyondspring, Inc. (NASDAQ: BYSI) Q4 2021 earnings call dated Apr. 14, 2022 Presentation: Operator Good morning, and welcome to BeyondSpring’s Fourth Quarter and Year End 2012 Financial Results Conference Call…. […] The post Beyondspring, Inc. (BYSI) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable 2022/02/12 15:00:00 Stocks Register
BeyondSpring Inc. (NASDAQ:BYSI) price on Friday, February 11, fall -4.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.97. A look at the stocks price movement, the close in the last trading session was $3.12, moving within a range at $2.945 and $3.145. The beta value (5-Year BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable Read More »
BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback. 2022/02/05 16:30:00 Marketing Sentinel
In last trading session, BeyondSpring Inc. (NASDAQ:BYSI) saw 0.32 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $3.07 trading at $0.08 or 2.68% at ring of the bell on the day assigns it a market valuation of $113.01M. That closing price of BYSI’s stock is at … BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback. Read More »
BeyondSpring Cuts On-Third Of Its Workforce 2022/01/12 10:43:50 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) plans to reduce its U.S. workforce by 35% , including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the Full story available on Benzinga.com
BeyondSpring''s New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia 2021/12/15 15:23:52 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition. The comparison was made between cancer patients receiving plinabulin 40 mg Full story available on Benzinga.com
Long-termism as Investment Philosophy: Healthcare Investor Sangel Capital Expects to See Big Rise in Investment Value 2021/09/21 02:00:00 PR Newswire Asia (English)
SHENZHEN, China , Sept. 20\1, 2021 /PRNewswire/ -- The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China , is poised for strong growth as multiple biotech and pharmaceutical companies backed by Sangel''s venture funds have reported a succession of milestone achievements in 2021 that led to a substantial surge in their market valuation. The optimistic projection of Sangel Capital''s investment value came after the announcement of BeyondSpring''s positive topline results from its DUBLIN -3 registrational trial of plinabulin in August and the IPO plans of its portfolio companies earlier this year, including Denovo Biopharma, 3D Medicines and Sirnaomics. Over the past decade, Sangel Capital has grown into a leading venture investor and breakthrough company builder across the entire value chain of healthcare and biotech investment. "The past decade has seen us participate in an extensive range of investment opportunities spanning biomedicine, medical devices, healthcare, and biotech with most projects already yielding returns.
BeyondSpring posts biggest intraday loss after trial data; H.C. Wainwright cuts price target 2021/09/20 19:32:02 Seeking Alpha
Why Are BeyondSpring''s Shares Plunging Today? 2021/09/20 18:22:49 Business Insider Markets
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI ) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3
Why Are BeyondSpring''s Shares Plunging Today? 2021/09/20 18:22:48 Benzinga
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI ) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetaxel vs. docetaxel alone for 2nd/3rd line non-small cell lung cancer (NSCLC) patients with EGFR wild type. The data were presented at the European Society for Medical Oncology Congress ( ESMO21 ) 2021 failed to impress. The mean overall survival (OS) for the combination Full story available on Benzinga.com
Heres why BeyondSpring shares are up more than 25% on Monday 2021/09/20 17:14:54 Invezz
Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung cancer. This morning, however, the stock tanked over 25% as STAT (American health-oriented news website) published an article that said issues with the conduct and analysis []
The post Heres why BeyondSpring shares are up more than 25% on Monday appeared first on Invezz.